<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Endemic, <z:hpo ids='HP_0003745'>sporadic</z:hpo> and HIV-associated Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) <z:hpo ids='HP_0000001'>all</z:hpo> have a B-<z:mp ids='MP_0005384'>cell phenotype</z:mp> and a MYC translocation, but a variable association with the Epstein-Barr virus (EBV) </plain></SENT>
<SENT sid="1" pm="."><plain>However, there is still no satisfactory explanation of how EBV participates in the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>A recent investigation suggested that EBV-positive and EBV-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> have different cells of origin </plain></SENT>
<SENT sid="3" pm="."><plain>In particular, according to immunoglobulin gene mutation analysis, EBV-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> may originate from early centroblasts, whereas EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> seem to arise from postgerminal center B cells or memory B cells </plain></SENT>
<SENT sid="4" pm="."><plain>The appearance of a germinal center phenotype in EBV-positive cells might thus derive from a block in B-cell differentiation </plain></SENT>
<SENT sid="5" pm="."><plain>The exit from the germinal center involves a complex series of events, which require the activation of BLIMP-1, and the consequent downregulation of several target genes </plain></SENT>
<SENT sid="6" pm="."><plain>Here, we investigated the expression of specific miRNAs predicted to be involved in B-cell differentiation and found that hsa-miR-127 is differentially expressed between EBV-positive and EBV-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>In particular, it was strongly upregulated only in EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> samples, whereas EBV-negative cases showed levels of expression similar to <z:mpath ids='MPATH_458'>normal</z:mpath> controls, including microdissected germinal centers (GC) cells </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, we found evidence that hsa-miR-127 is involved in B-cell differentiation process through posttranscriptional regulation of BLIMP1 and XBP1 </plain></SENT>
<SENT sid="9" pm="."><plain>The overexpression of this miRNA may thus represent a key event in the <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> of EBV positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, by blocking the B-cell differentiation process </plain></SENT>
</text></document>